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Abstract
Objectives. To examine temporal trends in all-cause and cause-specific mortality in RA.
Methods. Data from the Clinical Practice Research Datalink were used. Incident RA cases and four age-,
sex- and general practicematched controls were identified from at-risk cohorts for each calendar year
and followed-up for up to 5 years. Mortality rates and 95% CIs were computed. Cox proportional hazard
ratios (HRs) were calculated to estimate associations and adjusted for covariates. The temporal trend in
mortality was examined using the Joinpoint regression program. Data management and analysis were
performed using Stata version 14.
Results. A total of 21 622 cases with incident RA and 86 488 controls were included. The mortality rate of
RA cases and controls was 26.90 (95% CI 25.87, 27.97) and 18.92 (18.48, 19.36)/1000 person-years,
respectively. The mortality rate in RA cases did not change significantly between 1990 and 2004 but
decreased by 7.7%/year between 2005 and 2009. However, the mortality rate in controls improved stead-
ily by 2.2%/year between 1990 and 2009. RA was associated with a 32% excess risk of mortality in the
entire cohort [adjusted HR 1.32 (95% CI 1.26, 1.38)], but this was only 15% in cases incident after 2006
[adjusted HR 1.15 (95% CI 1.03, 1.29)]. Similarly, the HR of death due to cardiovascular diseases
decreased in cases incident in recent years.
Conclusion. The mortality rate in RA cases incident after the year 2006 has declined significantly, with a
trend towards a decline in death from cardiovascular diseases. This could be due to improved manage-
ment of RA. However, even in cohorts from recent years, RA still associates with higher mortality rates.
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Rheumatology key messages
. Rheumatoid arthritis associates with excess mortality.
. The mortality rate of incident RA has decreased over time, with a significant reduction between 2004 and 2009.
. The risk of death due to cardiovascular causes has decreased in people with RA in recent years.
Introduction
RA is traditionally believed to confer a 5060% higher risk
of mortality [13]. However, a recent study from Canada
reported that RA cases incident between the years 2001
and 2006 had similar mortality as matched controls, while
another study using data from UK’s Health Improvement
Network reported elevated but improving mortality in RA
[4, 5]. Contrary to these studies, others report that the
excess mortality risk associated with RA has not improved
in cases incident in recent years [2, 610]. As mortality is
1Academic Rheumatology, Division of Rheumatology, Orthopaedics,
and Dermatology, School of Medicine, University of Nottingham,
Nottingham, UK, 2Division of Rheumatology, Allergy and Immunology,
Chang Gung Memorial Hospital, Taoyuan, Taiwan, 3Arthritis Research
UK Primary Care Centre, Keele University, Keele and 4Division of
Epidemiology and Public Health, School of Medicine, University of
Nottingham, Nottingham, UK
Correspondence to: Abhishek Abhishek, A-21, Academic
Rheumatology, Division of Rheumatology, Orthopaedics, and
Dermatology, School of Medicine, University of Nottingham,
Nottingham, NG5 1PB, UK.
E-mail: Abhishek.abhishek@nottingham.ac.uk
Submitted 06 September 2017; revised version accepted
15 January 2018
! The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in
any medium, provided the original work is properly cited.
RHEUMATOLOGY
Rheumatology 2018;57:977981
doi:10.1093/rheumatology/key013
Advance Access publication 23 February 2018
C
L
IN
IC
A
L
S
C
IE
N
C
E
D
ow
nloaded from
 https://academ
ic.oup.com
/rheum
atology/article-abstract/57/6/977/4904191 by U
niversity of Keele user on 05 Septem
ber 2018
the most definitive and significant outcome, it is important
to confirm if the excess risk of mortality associated with
RA has improved in cases incident in recent years who
have access to better treatment options. Thus the object-
ives of this study were to examine the temporal trends in
all-cause and cause-specific mortality among adults with
incident RA according to the calendar year of disease
onset.
Methods
Data from the Clinical Practice Research Datalink (CPRD)
were used in this study. The CPRD is one of the largest
databases of longitudinal primary care medical records.
Established in 1987, it contains anonymized health care
records from >13 million individuals and represents 8% of
the UK population at any time. The data in the CPRD
undergo thorough quality checks and are of a reliable re-
search standard, with a median 89% with confirmed diag-
nosis in validation studies [11].
This study was approved by the Independent Scientific
Advisory Committee of the Medicines and Healthcare
Products Regulatory Agency (15_101R) and included par-
ticipants contributing acceptable quality data between 1
January 1990 and 31 December 2014. Incident cases with
RA were identified from at-risk cohorts for each calendar
year. The at-risk cohorts comprised all individuals regis-
tered with up-to-standard practices during the year spe-
cified who were never coded as having RA before the
latest of the current registration date plus 365 days or 1
January of the calendar year specified and were >18
years of age on 1 January of that year. To be eligible as
an incident case, participants had to have at least 1 year
disease-free registration prior to the first date of RA diag-
nosis, as this reduces the risk of prevalent cases being
counted as incident cases [12]. RA was defined using 58
Read codes (supplementary Table S1, available at
Rheumatology online) [1, 13] and 93.1% of these included
RA or described complications. Four codes implying ju-
venile arthritis were included, as RA can be misdiagnosed
as juvenile arthritis in individuals >17 years of age.
Four controls matched for age (5 year age band), sex
and general practice (GP) surgery were randomly selected
from individuals without RA for each incident case from
the at-risk cohorts in that year. Each matched control was
allocated the index case’s date of RA diagnosis. Each
case and matched control was followed up for a max-
imum 5 years from the index date to allow equal follow-
up. Person-years of follow-up were calculated from the
index date to the earliest of the transfer out date, last
data collection date, death date or 5 years from the
index date. Data for the cause of death (1 January 1998
onwards), classified according to the International
Classification of Diseases, 10th revision, and provided
by the Office for National Statistics via CPRD linkage
was used to examine temporal trends in cause of death.
Statistical analysis
Mean (S.D.) and n (%) were used for descriptive statistics.
Mortality rates and 95% CIs were computed. The Cox
proportional hazard ratio (HR) was used to estimate the
association between RA and mortality in each at-risk
cohort constructed for individual calendar years. This
was adjusted for BMI, smoking status, alcohol intake
and Charlson comorbidity index (excluding codes for
RA) at the start of that year [14, 15]. The temporal trend
in risk of mortality was examined using the Joinpoint
regression program [16]. This uses Bayesian information
criterion to generate different numbers of joinpoints indi-
cating time points where the rate or hazard of occurrence
of an event changes significantly and to fit separate linear
trends in each time segment. Annual percentage changes
(APCs) for each segment were calculated. Competing risk
analysis was used to examine the association between RA
and death due to cardiovascular, neoplastic and respira-
tory causes, as they account for most of the deaths in RA
[17]. This was stratified for the year of incidence of
RA and the APC was calculated as above. Data manage-
ment and analysis were performed using Stata version 14
(StataCorp, College Station, TX, USA). The statistical
significance level was P< 0.05.
Results
Data for 21 622 cases with incident RA and 86 488
matched controls followed up for a mean of 4.31
(S.D. 1.27) and 4.37 (S.D. 1.23) years and contributing
93 122 and 378 002 person-years of data, respectively,
were included (supplementary Table S2, available at
Rheumatology online). There were 2505 (11.59%) and
7150 (8.27%) deaths at a mean age of 77.33 (S.D. 10.56)
and 79.09 (S.D. 10.28) years in cases and controls,
respectively (P< 0.001).
The mortality rates of RA cases and matched controls
were 26.90 (95% CI 25.87, 27.97) and 18.92 (18.48,
19.36)/1000 person-years, respectively. RA associated
with a higher risk of all-cause mortality [HR 1.42 (95%
CI 1.36, 1.49) overall, 1.43 (1.33, 1.54) for men and 1.42
(1.34, 1.50) for women], which remained significant after
adjusting for covariates [adjusted HR 1.32 (95% CI 1.26,
1.38) overall, 1.31 (1.21, 1.41) for men, 1.33 (1.25, 1.41) for
women].
RA cases and matched controls from recent calendar
years demonstrated lower all-cause mortality than that
observed in earlier years (supplementary Fig. S1, available
at Rheumatology online). On joinpoint analysis the 5 year
mortality rate for RA cases did not change between 1990
and 2004, but decreased significantly by 7.7%/year (95% CI
1.9, 13.3) between 2004 and 2009, with a statistically sig-
nificant joinpoint in the year 2004 (supplementary Fig. S2,
available at Rheumatology online). In contrast, the 5 year
mortality rates for matched controls decreased by 2.2%/
year (95% CI 3, 1.3) between 1990 and 2009, with no
statistically significant joinpoint.
Similar to the improvements in all-cause mortality rate,
the HR of mortality associated with RA in recent years has
improved (Table 1). Findings from recent years suggest a
non-significant increase in the risk of mortality associated
with RA. However, this may be due to a lack of power, and
when data from 2007 to 2009 were pooled there was a
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15% higher risk of mortality in cases incident in these
years (Table 2).
Data for cause of death were available for 53 949 par-
ticipants (10 841 cases, 43 108 controls) with index date 1
January 199831 December 2009. RA associated with an
elevated risk of death from cardiovascular, respiratory and
neoplastic causes (Table 2). There was a statistically non-
significant trend towards a decline in the risk of death due
to cardiovascular causes [APC 3.6 (95% CI 8.1, 1.1),
P= 0.10] in this period, while the risk of death due to
respiratory and neoplastic causes remained stable [APC
1.8 (95% CI 7.9, 4.0), P= 0.5; 1.2 (6.7, 4.6), P= 0.7,
respectively].
Discussion
This study demonstrates that the increased risk of death
associated with RA has decreased in cases incident after
the year 2004 but is still higher than in matched controls.
We built separate incidence cohorts for each year that
allowed us to examine the effects of treatment paradigm
in the calendar and subsequent years on the mortality risk
of cases incident in that year. This is a significant advance
on previous studies that merged cases from several years
into two distinct cohorts [4, 5]. Additionally, the findings of
this study have greater validity than previous studies, as
we included a longer study period (19902014), had con-
temporaneous matched controls and used competing risk
analysis when estimating the risk of cause-specific
mortality. Moreover, joinpoint analysis allows us to identify
the year in which excess mortality associated with RA
began to decrease.
The mortality rates reported in this study are consistent
with previous reports [5, 8, 10]. We observed a steady
decline in mortality in controls between the years 1990
and 2014, whereas there was a significant reduction in
the risk of death in RA cases incident after the year
2004. This suggests that the adoption of early combin-
ation DMARD treatment, supported by biologics when
indicated, may have saved lives of RA cases incident in
recent years [18, 19].
As previously reported, we observed a trend towards a
reduction in the risk of death from cardiovascular diseases
[4]. However, the elevated risk of death due to respiratory
diseases and neoplasms appeared to be stable in this
study, in contrast to previous reports [4]. This raises the
possibility that improved control of inflammation in RA
with the availability of better treatment options has trans-
lated into reduced cardiovascular mortality, potentially via
an effect on stabilizing the progression of atherosclerosis
[20], but has not reduced mortality risk due to neoplasms
and respiratory causes.
A previous study using data from the Health
Improvement Network reported that RA cases incident
between 1999 and 2006 and 2007 and 2014 had 56 and
29% higher risk of death, respectively [5]. This is higher
than the overall mortality risk reported in our study. We
found RA cases incident between 2007 and 2009 to only
have a 15% excess mortality risk, which is lower than the
risk of mortality (cf. 3246%) in cases incident in earlier
years. Our study with a longer period of follow-up allows
an independent corroboration of the previous studies
examining temporal trends in RA mortality.
The improvement in mortality in people with RA is not
due to screening for cardiovascular diseases, as this was
included in the Quality and Outcomes Framework, a
mechanism by which GP surgeries were rewarded finan-
cially for taking better care of people with certain condi-
tions in the year 2014. It is possible that this improvement
in mortality is due to the availability of anti-CCP antibody
testing in the UK, which would result in a greater propor-
tion of people with inflammatory arthritis being diagnosed
with RA and receiving combination DMARDs.
In this study we used 1 year disease-free up to standard
registration in the CPRD to define incident RA cases, be-
cause the incidence of RA does not vary when increasing
this to 3 years [1]. Additionally, we used the first Read code
for RA to define incident RA. Others have used one Read
code of an RA diagnosis and one DMARD prescription to
define cases as having RA. We believe that the latter
method may induce ascertainment bias in defining incident
RA cases in a study spanning >20 years during which
DMARD prescribing practices have changed, with a
>100% increase in the uptake of DMARDs over time.
Therefore, selecting cases with RA based on at least one
prescription for a DMARD would result in only more severe
cases being included in earlier cohorts, while the latest co-
horts could have the full spectrum of RA cases, both mild
TABLE 1 Risk of mortality associated with RA cases in-
cident in each calendar year compared with controls
Year HR (95% CI)a Adjusted HR (95% CI)b
1990 1.48 (1.15, 1.91) 1.30 (1.01, 1.67)
1991 1.57 (1.19, 2.07) 1.53 (1.15, 2.02)
1992 1.15 (0.86, 1.52) 1.21 (0.91, 1.61)
1993 1.49 (1.14, 1.94) 1.53 (1.17, 2.00)
1994 1.45 (1.11, 1.91) 1.51 (1.15 1.99)
1995 1.28 (0.95, 1.71) 1.23 (0.91 1.66)
1996 1.17 (0.89, 1.55) 1.19 (0.90 1.57)
1997 1.40 (1.11, 1.76) 1.45 (1.15, 1.82)
1998 1.40 (1.11, 1.78) 1.44 (1.13, 1.83)
1999 1.43 (1.16, 1.75) 1.31 (1.07, 1.62)
2000 1.65 (1.39, 1.95) 1.58 (1.32, 1.88)
2001 1.68 (1.42, 1.98) 1.69 (1.43, 1.99)
2002 1.51 (1.29, 1.77) 1.48 (1.26, 1.73)
2003 1.36 (1.16, 1.60) 1.25 (1.06, 1.48)
2004 1.54 (1.33 1.78) 1.42 (1.22, 1.65)
2005 1.35 (1.12, 1.62) 1.22 (1.01, 1.46)
2006 1.40 (1.18, 1.67) 1.27 (1.06, 1.51)
2007 1.31 (1.08, 1.58) 1.14 (0.94, 1.38)
2008 1.21 (1.01, 1.46) 1.11(0.92, 1.33)
2009 1.35 (1.10 1.66) 1.18 (0.96, 1.45)
aAge, sex and GP surgery matched. bMatched analysis ad-
justed for BMI (<20, 2024.99, 2529.99, 3039.99,540kg/m2,
missing), smoking status (current smoker, ex-smoker, non-
smoker, missing data), alcohol intake (currently, previously,
never, missing data) and Charlson comorbidity index (0, 1, 52).
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and severe. Such an inclusion criteria would bias the study
towards showing a temporal trend in mortality reduction.
There are several caveats to this study. First, RA is diag-
nosed by hospital rheumatologists in the UK and the
coding in the CPRD is likely to lag behind the diagnosis
by several weeks due to the time taken for clinic letters
to arrive in GP surgeries. Thus some cases coded as
having RA in 1 year may have been diagnosed in the pre-
vious year. However, this is unlikely to play a significant
role, as misclassification from consecutive calendar years
is likely to cancel out effects on the temporal trend.
Second, the CPRD is a consultation-based database and
comorbidities are recorded only if a patient consults for
them. Finally, we are unable to provide a reason for the
reduction in mortality in RA and are only able to speculate
that this is due to improved management of RA in recent
years. However, given the degree of improvement in RA
mortality and changes in the paradigm of treatment of RA
in the early 2000s, this seems likely. The CPRD is limited by
the absence of detailed phenotyping of RA cases, for ex-
ample, information on affected joints is not recorded. We
are therefore unable to specify the proportion of cases who
meet the 2010 ACR/EULAR classification criteria for RA.
Another limitation is that we examined mortality in the
first 5 years of disease, and further research is required
to understand if this trend persists in the long term.
In conclusion, the risk of mortality due to RA improved
after 2004, with a continuing decline in recent years, and is
likely to be attributed to improving cardiovascular mortality.
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